Another national database study showed that the favorable effect of DPP4-inhibitors on CRC patients did not reach the statistical significance (HR of 0.87; CI: 0.75–1.00, p = 0.055), while significant improvement in survival was achieved by administration of synergic DPP4-inhibitors and metformin (HR of 0.77; CI: 0.67–0.89, P = 0.003) [24]. The gene discussed is DPP4; the disease is colorectal carcinoma.